From John Money to Modern Gender Clinics: An Insider Speaks - Dr. Quentin Van Meter (#28)
11 August 2025
With Quentin Van Meter
Global
Dr. Quentin Van Meter trained at Johns Hopkins alongside John Money and has practised paediatric endocrinology for over four decades. In this episode he traces how gender medicine moved from unregulated experiment to mainstream clinical practice, questions the evidence base underpinning bodies such as WPATH, and explains why the near-universal progression from puberty blockers to cross-sex hormones matters. Ireland's health services draw on the same international guidelines Van Meter critiques, making his testimony relevant to anyone following the direction of Irish paediatric care.
Dr. Quentin Van Meter is a paediatric endocrinologist with more than four decades of clinical experience who was present at the origins of paediatric gender medicine. His fellowship at Johns Hopkins placed him in direct contact with Dr. John Money, whose theories about the malleability of gender identity provided the intellectual foundations for the field. Van Meter treated his first child presenting with gender distress in 1993, before any clinical guidelines existed, and has watched the discipline transform into what he now describes as a closed ideological system rather than an evidence-based speciality. Money promoted the idea that gender identity could be shaped independently of biological sex, and Van Meter describes witnessing that theory applied in practice — including a case in which Money sought to surgically alter an infant with normal testosterone levels. This history matters because the organisations that now set international guidelines, including WPATH, trace their theoretical lineage directly to Money's framework. WPATH's standards of care are referenced by clinicians in Ireland and across Europe, making the questions Van Meter raises about those foundations directly relevant to how paediatric care is delivered here. His central clinical concern focuses on the pathway from puberty blockers to cross-sex hormones. He cites evidence that approximately 98 per cent of children who receive puberty-suppressing drugs go on to receive cross-sex hormones, suggesting the blocker pathway functions not as a neutral pause but as a near-certain first step toward permanent medical intervention. He also raises the question of cognitive effects, citing evidence linking prolonged sex-hormone suppression to risks for brain health — concerns that have featured in independent reviews of paediatric gender medicine in several countries. Van Meter's assessment of WPATH is stark. He describes the organisation as having abandoned scientific rigour in favour of ideological adherence, and his 2018 talk, "The Terrible Fraud of Transgender Medicine," argued that the evidence base for paediatric gender transition was constructed rather than discovered. He subsequently resigned from the American Academy of Pediatrics over what he characterises as a policy on transgender care that was not grounded in the evidence available to the organisation. In Ireland, the National Gender Service operates as the primary HSE route for gender-related care, and Irish clinical practice draws on WPATH standards of care. Ireland has not completed an independent review of its paediatric gender medicine protocols comparable to the Cass Review, which was published in 2024 and reached similar conclusions about the evidence base from within the NHS. Van Meter's account — from a clinician who was in the room when the field was being built — offers a detailed perspective on why that kind of scrutiny matters, and why the children at the centre of these decisions bear the consequences when medicine follows ideology rather than evidence.
